Pain reprocessing therapy produced small but measurable reductions in cross-modal sensory amplification, pointing to a broader neurological signature of chronic back pain than previously recognized.
Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk
What people hear and do not hear can have a direct effect on their balance, according to new research from the New York Eye and Ear Infirmary of Mount Sinai (NYEE).